These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 9474874)

  • 1. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
    Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
    Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
    Lax SF
    Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular carcinogenesis of endometrial cancer.
    Liu FS
    Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theories of endometrial carcinogenesis: a multidisciplinary approach.
    Sherman ME
    Mod Pathol; 2000 Mar; 13(3):295-308. PubMed ID: 10757340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis in endometrial cancer.
    Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
    Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endometrial carcinoma and precursor lesions].
    Djordjević B; Stanojević Z
    Srp Arh Celok Lek; 2007; 135(3-4):230-4. PubMed ID: 17642468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
    Jia L; Liu Y; Yi X; Miron A; Crum CP; Kong B; Zheng W
    Clin Cancer Res; 2008 Apr; 14(8):2263-9. PubMed ID: 18369088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
    Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
    Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
    Cao SN; Chang KH; Luthra R; Liu J
    Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
    Schlosshauer PW; Ellenson LH; Soslow RA
    Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium.
    Lax SF
    Pathology; 2007 Feb; 39(1):46-54. PubMed ID: 17365822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.